Emerging drugs for the treatment of pancreatic cancer

Area of Science:

• Oncology
• Gastroenterology
• Translational Medicine

Background:

• Pancreatic cancer treatment remains a significant challenge, with limited therapeutic advances and predominantly palliative care options.
• Gemcitabine is the current standard of care for advanced pancreatic cancer, but its efficacy is limited, necessitating the exploration of novel therapeutic strategies.
• Understanding the aggressive tumoral phenotype and identifying new therapeutic targets are crucial for improving patient survival benefits.

Purpose of the Study:

• To review current challenges and explore promising therapeutic avenues for pancreatic cancer management.
• To highlight the potential of targeted therapies, including anti-EGFR, antiangiogenic agents, and multi-targeted small molecules.
• To emphasize the need for translational research and personalized medicine approaches in pancreatic cancer treatment.

Main Methods:

• Review of current literature on pancreatic cancer treatment strategies.
• Analysis of the role of targeted agents and combination therapies.
• Discussion of the importance of translational research and biomarker identification.

Main Results:

• Despite extensive research, advances in pancreatic cancer management and survival remain poor.
• Targeted therapies, such as anti-EGFR and antiangiogenic agents, show potential but require further development and optimal integration.
• Multi-targeted agents and receptor tyrosine kinase inhibitors offer promising avenues for preclinical and clinical investigation.

Conclusions:

• Novel therapeutic strategies, including targeted agents and combination therapies, are essential for improving pancreatic cancer outcomes.
• Further research is needed to identify new molecular targets and predictive biomarkers for patient selection.
• Integrating translational research and evaluating therapies in the perioperative setting are critical for advancing curative approaches.